Portfolio
We seek investments in innovative companies that are developing first-in-class products for growth markets. Investments have been made in various therapeutic areas, including oncology, inflammation, cardiovascular, metabolic and CNS.
Fibrex Medical - Austria | |||
| Fund engagement: | 2006 | Activity: | Drug development Reperfusion injury |
| Status: | Exited - Licensing | Contact: | www.fibrexmedical.com |
Elara Phamraceuticals - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development HIF pathway |
| Status: | Pre-clinical development | Contact: | www.elarapharma.com |
Lipid Therapeutics - Germany | |||
| Fund engagement: | 2008 | Activity: | Drug development Colitis ulcerosa |
| Status: | Partnered - Phase IIB | Contact: | www.lipid-therapeutics.com |
Affectis Pharmaceuticals - Germany | |||
| Fund engagement: | 2005 | Activity: | Drug development Depression |
| Status: | Partnered - Preclinical | Contact: | www.affectis.com |
Immatics - Germany | |||
| Fund engagement: | 2004 | Activity: | Drug development Cancer vaccines |
| Status: | Clinical phase II/III | Contact: | www.immatics.com |
Endoart - Switzerland | |||
| Fund engagement: | 2006 | Activity: | Medtech Obesity |
| Status: | Exited - Aquisition | Contact: | n.a. |
Vasopharm - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Traumatic brain injury |
| Status: | Clinical phase IIA | Contact: | www.vasopharm.com |
Hybricore - Germany | |||
| Fund engagement: | 2003 | Activity: | Services Antibody production |
| Status: | Exited - Licensing | Contact: | n.a. |
Combinature - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Anti-infectives |
| Status: | Exited - Secondary transaction | Contact: | n.a. |
Jado Technologies - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Allergy |
| Status: | Preclinical | Contact: | www.jado-tech.com |
Cenix Bioscience - Germany | |||
| Fund engagement: | 2002 | Activity: | Services RNAi based target discovery |
| Status: | Profitable | Contact: | www.cenix.com |
ArthroKinetics - Germany | |||
| Fund engagement: | 2003 | Activity: | Medtech Cartilage replacement |
| Status: | Exited - IPO | Contact: | www.arthro-kinetics.com |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
"Moving a project from a research lab to a company is a daunting process. When the ideas we generated in the lab warranted the establishment of Elara Pharmaceuticals, the task of converting an idea into a commercial entity was greatly helped by EMBL Ventures. Every step of the process has been guided by their expertise. Their task is a delicate one as they have to understand the mentality of the founders and the funders and to achieve benefits for both sides. From our experience with Elara Pharmaceuticals, EMBL Ventures succeeded exceptionally well in achieving our mutual goals."
Prof. Frank Gannon, PhD; Science Foundation Ireland, former Director of EMBO and co-founder of Elara Pharmaceuticals